#ICYMI Matthew Herper of STAT sat down with our CEO, Dr. J. Jean Cui, to learn more about her story and our mission to develop effective #cancer therapeutics that tackle drug resistance. Read the full article here: bit.ly/49NRCLA

We’re looking forward to presenting at #AACR24! Don’t miss our poster presentations featuring preclinical data from our CLK inhibitor program. See more details below and view our abstracts here: bit.ly/3xkGmYM and bit.ly/49gHCJI AACR

We are thrilled to see our CEO, Dr. J. Jean Cui, featured in The Medicine Maker 2024 Power List for pioneering several cutting-edge medicines for patients in need. Join us in congratulating Dr. Cui on this recognition! More here: bit.ly/3Jm09K4

Our President & CEO Dr. J. Jean Cui was recognized as one of the 11 Asian American executives shaping the future of biopharma by the Timmerman Report. This accolade underscores Jean’s outstanding leadership, vision, and unwavering dedication to patients. bit.ly/3VuEK8r

Geoff Oxnard, M.D., joins BlossomHill as CMO & EVP, and Ashley Preston, Ph.D., as SVP, Head of Regulatory Affairs & QA. Their leadership will be important as we advance our first two #oncology programs through #clinical studies. Read more: bit.ly/4fU80Na

Today, we announced the first cohort of patients has been dosed in the Phase 1/2 SOLARA #clinicaltrial for the study of our first-in-class macrocyclic OMNI-EGFR inhibitor, BH-30643, in EGFR & HER2 mutated #NSCLC. Read the press release here: businesswire.com/news/home/2025… #cancer

BlossomHill Therapeutics, Inc. appoints Jason Keyes as Chief Financial Officer and Executive Vice President. BlossomHill is thrilled to welcome Jason to our Executive Leadership Team and look... globenewswire.com/NewsRoom/Relea…

#BlossomHill is looking forward to educating the #pharma community on our non-covalent, macrocyclic, mutant-selective OMNI-EGFR inhibitor, BH-30643, at #ASCO25 with two posters!! See you in Chicago! Links: meetings.asco.org/abstracts-pres… meetings.asco.org/abstracts-pres… #EGFR #NSCLC #cancer

We are very excited to announce the first patient dosed in the expansion cohorts of our #Solara trial studying BH-30643! "Our goal at #BlossomHill is to make the next leap forward in the... globenewswire.com/NewsRoom/Relea…

We’re excited to present @ AACR-NCI-EORTC International Conference w/ preliminary findings from the dose escalation portion of our ongoing, first-in-human Phase 1/2 SOLARA trial of BH-30643, a first-in-class, macrocyclic, non-covalent, OMNI-EGFR™. globenewswire.com/news-release/2…

Exciting early #SOLARATrial data from BH-30643 @ #AACR-#NCI-#EORTC showing tumor reductions & potential to overcome resistance in #EGFR-mutant #NSCLC. W/ its novel macrocyclic design, BH-30643 has potential to make a leap forward in #oncology innovation. globenewswire.com/news-release/2…

We're presenting our ongoing, first-in-human, Phase 1/1b dose escalation study of BH-30236, our highly potent & selective CLK inhibitor, in relapsed/refractory acute myeloid #leukemia & higher-risk #myelodysplastic syndrome, @ the 67th #ASH25 #AML #HRMDS bhtherapeutics.com/press-releases…

We're on the road to present at the Guggenheim Securities 2nd Annual Healthcare Innovation Conference in Boston and also attending the #JeffriesHealthcare Global Conference in London, where we’ll be taking 1x1 meetings to discuss our science and pipeline. See you there!

Today, we announced the closing of an $84 million financing to accelerate our clinical-stage pipeline of intelligently designed #cancer medicines. Learn more from our Executive VP & CFO, Jason Keyes, below, & here: bhtherapeutics.com/press-releases…

Our President & CEO J. Jean Cui, & CMO Geoff Oxnard, will dive into our clinical-stage pipeline at #JPM26, including BH-30643, our OMNI-EGFR™ in #NSCLC, & progress on BH-30236, a CLK inhibitor targeting aberrant RNA splicing in #cancer. globenewswire.com/news-release/2…

Excited to be @ #TTLC in Huntington Beach this week. We're sponsoring Networking Breakfasts in Salon ABC from 7–8:15 AM Feb 19–21. Stop by for coffee & to talk targeted therapies w/ Geoff Oxnard & our clinical leadership. Thanks to #IASLC for the opportunity to host these events!

We’re introducing our next-generation KRAS pipeline at #AACR26 in San Diego as well as new preclinical data for BH-30643 and BH-30236. Learn more: globenewswire.com/news-release/2…

We presented new preclinical data at #AACR2026, including BH-501284, our novel pan-KRAS inhibitor. We’re also sharing updates on BH-30643 (OMNI-EGFR™) and BH-30236 (CLK). Looking forward to connecting with the oncology community. globenewswire.com/news-release/2…

BlossomHill CMO, Dr. Geoff Oxnard, will present at the 8th Annual RAS-Targeted Drug Development Summit this September, where he will discuss a differentiated chemical design allowing pseudo-irreversible, dual-state, allosteric inhibition of KRAS across diverse mutations.

We're excited to present initial dose escalation data from the Phase 1/1b trial of BH-30236, our macrocyclic CLK inhibitor, at #EHA2026 in Stockholm. The FDA has granted Orphan Drug Designation to BH-30236 for the treatment of AML. bhtherapeutics.com/press-releases…